作者: Grant A. McArthur , Igor Puzanov , Ravi Amaravadi , Antoni Ribas , Paul Chapman
关键词: Vemurafenib 、 Fluorodeoxyglucose 、 Mutant 、 Melanoma 、 Fluorodeoxyglucose positron emission tomography 、 Pathology 、 Advanced melanoma 、 Medicine 、 Homogeneous 、 Cancer research 、 Positron emission tomography
摘要: Purpose Imaging with [ 18 F]fluorodeoxyglucose (FDG) –positron emission tomography (PET) allows early recognition of a response to agents that target key driver mutations in human cancer. We aimed determine the metabolic rate vemurafenib patients advanced BRAF-mutant melanoma.